148 related articles for article (PubMed ID: 23588637)
1. Prognostic value of Pheochromocytoma of the Adrenal Gland Scaled Score (Pass score) tests to separate benign from malignant neoplasms.
Mlika M; Kourda N; Zorgati MM; Bahri S; Ben Ammar S; Zermani R
Tunis Med; 2013 Mar; 91(3):209-15. PubMed ID: 23588637
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas.
Gao B; Meng F; Bian W; Chen J; Zhao H; Ma G; Shi B; Zhang J; Liu Y; Xu Z
Urology; 2006 Aug; 68(2):282-6. PubMed ID: 16904437
[TBL] [Abstract][Full Text] [Related]
3. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.
Thompson LD
Am J Surg Pathol; 2002 May; 26(5):551-66. PubMed ID: 11979086
[TBL] [Abstract][Full Text] [Related]
4. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T.
Dong Y; Liu Q
J Comput Assist Tomogr; 2012; 36(4):361-6. PubMed ID: 22805661
[TBL] [Abstract][Full Text] [Related]
6. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
7. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
8. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score.
Wu D; Tischler AS; Lloyd RV; DeLellis RA; de Krijger R; van Nederveen F; Nosé V
Am J Surg Pathol; 2009 Apr; 33(4):599-608. PubMed ID: 19145205
[TBL] [Abstract][Full Text] [Related]
9. Morphometric analysis of benign and malignant adrenal pheochromocytomas.
Hoffman K; Gil J; Barba J; Liu Z; Pertsemlidis D; Kaneko M; Unger P
Arch Pathol Lab Med; 1993 Mar; 117(3):244-7. PubMed ID: 8442669
[TBL] [Abstract][Full Text] [Related]
10. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
[TBL] [Abstract][Full Text] [Related]
11. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of morphology of adrenal pheochromocytoma as regards their potential malignancy].
Kajor M; Ziaja J; Lange D; Król R; Ciupińska-Kajor M; Turska-d'Amico M; Maka B; Cierpka L
Endokrynol Pol; 2005; 56(6):911-6. PubMed ID: 16821210
[TBL] [Abstract][Full Text] [Related]
13. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
[TBL] [Abstract][Full Text] [Related]
14. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
[TBL] [Abstract][Full Text] [Related]
15. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?
Agarwal A; Mehrotra PK; Jain M; Gupta SK; Mishra A; Chand G; Agarwal G; Verma AK; Mishra SK; Singh U
World J Surg; 2010 Dec; 34(12):3022-8. PubMed ID: 20703467
[TBL] [Abstract][Full Text] [Related]
16. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas.
Shen WT; Sturgeon C; Clark OH; Duh QY; Kebebew E
Surgery; 2004 Dec; 136(6):1129-37. PubMed ID: 15657566
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytomas, PASS, and immunohistochemistry.
Carlsen E; Abdullah Z; Kazmi SM; Kousparos G
Horm Metab Res; 2009 Sep; 41(9):715-9. PubMed ID: 19718615
[TBL] [Abstract][Full Text] [Related]
18. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.
Stenman A; Svahn F; Hojjat-Farsangi M; Zedenius J; Söderkvist P; Gimm O; Larsson C; Juhlin CC
Am J Surg Pathol; 2019 Mar; 43(3):409-421. PubMed ID: 30451732
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
Białas M; Okoń K; Dyduch G; Ciesielska-Milian K; Buziak M; Hubalewska-Dydejczyk A; Sobrinho-Simoes M
Pol J Pathol; 2013 Jun; 64(2):129-35. PubMed ID: 23900871
[TBL] [Abstract][Full Text] [Related]
20. [Pheochromocytoma and sympathetic paragangliomas].
Zollinger R; Hedinger C
Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
